Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
South Korean military plans to launch new division for future warfare
-
7
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
PM orders full review of EMA's findings before resuming use of AstraZeneca's vaccine
By YonhapPublished : April 8, 2021 - 11:53
Prime Minister Chung Sye-kyun on Thursday ordered health authorities to thoroughly and swiftly review the latest findings by the European Medicines Agency (EMA) on the safety of AstraZeneca's vaccine.
The Korea Disease Control and Prevention Agency should "swiftly reach a scientific conclusion on the findings and share the results with the public in a transparent manner," he said.
While rare blood clots have been reported among people administered with the vaccine, the EMA said "the benefits (of administering the vaccine) outweigh the risks," he added.
On Wednesday, the country suspended the use of AstraZeneca's vaccine for people under age 60, special education instructors and school nurses to "prioritize people's health and safety." Later that day, the EMA announced there is a "possible link" between the vaccine and unusual blood clot cases.
The government will decide on resuming use of AstraZeneca's vaccine for the group after closely analyzing the EMA's findings, Chung said.
"We will focus on devising effective antivirus measures as the country is at risk of entering a fourth wave of infections," he said. (Yonhap)
The Korea Disease Control and Prevention Agency should "swiftly reach a scientific conclusion on the findings and share the results with the public in a transparent manner," he said.
While rare blood clots have been reported among people administered with the vaccine, the EMA said "the benefits (of administering the vaccine) outweigh the risks," he added.
On Wednesday, the country suspended the use of AstraZeneca's vaccine for people under age 60, special education instructors and school nurses to "prioritize people's health and safety." Later that day, the EMA announced there is a "possible link" between the vaccine and unusual blood clot cases.
The government will decide on resuming use of AstraZeneca's vaccine for the group after closely analyzing the EMA's findings, Chung said.
"We will focus on devising effective antivirus measures as the country is at risk of entering a fourth wave of infections," he said. (Yonhap)
